BAX and acute kidney injury: The interplay between PU's NRF2/NQO1 pathway activation and Bax/c‐caspase3 signaling pathway modulation provides a plausible explanation for its efficacy against cisplatin‐induced AKI, warranting further exploration to elucidate PU's underlying mechanisms in AKI management.